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Abstract Microglial nodules in the normal-appearing
white matter have been suggested as the earliest stage(s) of
multiple sclerosis (MS) lesion formation. Such nodules are
characterized by an absence of leukocyte infiltration,
astrogliosis or demyelination, and may develop into active
demyelinating MS lesions. Although the etiology of MS is
still not known, inflammation and autoimmunity are con-
sidered to be the central components of this disease.
Previous studies provide evidence that Wallerian degen-
eration, occurring as a consequence of structural damage in
MS lesions, might be responsible for observed pathological
abnormalities in connected normal-appearing white matter.
As innate immune cells, microglia/macrophages are the
first to react to even minor pathological changes in the
CNS. Biopsy tissue from 27 MS patients and autopsy and
biopsy tissue from 22 normal and pathological controls
were analyzed to determine the incidence of microglial
nodules. We assessed MS periplaque white matter tissue
from early disease stages to determine whether microglial
nodules are associated with altered axons. With immuno-
histochemical methods, the spatial relation of the two
phenomena was visualized using HLA-DR antibody for
MHC II expression by activated microglia/macrophages
and by applying antibodies against damaged axons, i.e.,
SMI32 (non-phosphorylated neurofilaments) and amyloid
precursor protein as well as neuropeptide Y receptor Y1,
which marks axons undergoing Wallerian degeneration.
Our data demonstrate that the occurrence of microglial
nodules is not specific to MS and is associated with
degenerating as well as damaged axons in early MS. In
addition, we show that early MS microglial nodules exhibit
both pro- and antiinflammatory phenotypes.
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Introduction
Multiple sclerosis (MS) is a chronic inflammatory CNS
disease characterized by multifocal inflammation, exten-
sive demyelination, gliosis and axonal damage. The
etiology of MS is still not known, and the first cellular
events in the MS brain remain to be clarified. Microglia are
the resident immune cells that react to even minor patho-
logical events in the CNS [27], and microglial activation
might arguably be considered an initial pathogenetic event
in MS. Inflammation and microglia/macrophage activation
may cause myelin/axonal damage or, alternatively, the
cells may scavenge damaged myelin/axonal debris. A
cluster of activated microglia/macrophages is commonly
termed a ‘microglial nodule’ without a strict definition of
the cell number. Studies of post-mortem MS brain tissues
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have proposed that microglia nodules observed in the so-
called normal-appearing white matter (NAWM) may rep-
resent the earliest stage(s) in MS lesion development and
were therefore called (p)reactive lesions [13, 46, 52, 55].
Such nodules are identified in the absence of leukocyte
infiltration, astrogliosis or demyelination [53, 55].
Microglial nodules are a well-known phenomenon in viral
encephalitis, in which perineuronal aggregation of acti-
vated microglia/macrophages indicative of neuronal
phagocytosis is often observed. Furthermore, phagocytosis
of neuroaxonal debris by activated microglia/macrophages
is in agreement with prior observations in MS [25]. In fact,
activated microglia/macrophages also release a wide range
of cytotoxins, free radicals, neurotrophic factors and
immunomodulatory molecules, which may reflect immu-
noregulatory rather than just proinflammatory activity
[8, 23]. Two extremes of these activation states are clas-
sically activated (M1) and alternatively activated (M2)
macrophages.
Axonal transection within the lesion, causing antero-
grade degeneration of the distal part of the axon—also
known as Wallerian degeneration—might occur diffusely
in the tissue surrounding the lesion, inducing microglial/
macrophage reaction to absorb axonal and myelin frag-
ments in non-demyelinated MS white matter. Moreover,
results of several neuropathological and neuroradiological
studies confirmed Wallerian degeneration in early MS
NAWM [10, 11, 18, 21, 48]. Based on MS periplaque
white matter (PPWM) biopsy tissue, a recent study using
an antibody against the neuropeptide Y receptor Y1 (NPY-
Y1R) also showed widespread Wallerian degeneration
[19]. The antigen detected by the anti-NPY-Y1R antibody
remains to be determined. It is however known that
peripheral nerve injury induces increased NPY expression
in dorsal root ganglion neurons in rodents, and receptor Y1
is upregulated in neurons [12, 57, 58, 61]. Thus, it is
possible that NPY-Y1R plays a role in promoting survival
during degenerative processes.
The main aim of our study was to investigate white
matter biopsy tissue from early stage MS patients in order
to determine whether axonal alterations are present in
microglial nodules. To do so, we used anti-HLA-DR (an
antigen belonging to human leukocyte-associated antigens
class II) antibody for activated microglia/macrophages and
three different immunohistochemical markers for damaged
axons, i.e., SMI32, which reacts to damaged axons with
non-phosphorylated neurofilaments; amyloid precursor
protein (APP) as a marker for transport disturbance in
acutely damaged axons; and NPY-Y1R for axons
undergoing Wallerian degeneration. Subsequently, we
characterized the immune phenotype of MS microglial
nodules using M1 and M2 macrophage markers. Based on
the literature, we selected antibodies directed against CD40
and inducible nitric oxide synthase (iNOS) as M1 markers
and mannose receptor and CD163 as M2 markers [3, 5, 23,
26, 62]. A better understanding of pathological processes in
non-demyelinated white matter in early MS may enable




We investigated biopsy tissue from 27 patients who had
been diagnosed with inflammatory demyelination of the
CNS consistent with MS. A total of 44 tissue blocks, which
included non-demyelinated white matter regions, were
used for the study. The biopsies were performed in dif-
ferent neurosurgery centers for various diagnostic reasons,
for example, to exclude neoplastic or infectious diseases.
Informed consent had been obtained from each patient.
None of the study authors was involved in decision making
with respect to biopsy. However, histology showed
inflammatory demyelinating lesions typical for MS. Spec-
imens were sent to the Department of Neuropathology in
Go¨ttingen, Germany, for a second opinion. Patients
received the diagnosis of MS according to the McDonald’s
or Poser’s criteria [36, 43]. Of the 27 patients, 8 underwent
comprehensive clinical follow-up: 6 patients (MS nos. 3, 4,
7, 13, 19, 25) had a relapsing-remitting course, MS no. 11
showed all the characteristics of primary progressive MS
[51], and MS no. 27 entered a secondary progressive dis-
ease course years after biopsy. All the other 19 patients
were diagnosed with clinically isolated syndrome sugges-
tive of MS. Patient characteristics are summarized in
Supplement 1.
We also analyzed archival paraffin-embedded brain
tissue obtained from seven brain infarct (four autopsy and
three biopsy) cases, three traumatic brain injury (TBI)
autopsies, and seven biopsies from patients who underwent
surgery for temporal lobe epilepsy. The control group
consisted of autopsy CNS tissue from five patients who
died suddenly because of non-neurological disorders. No
neurological abnormalities were found in any routine
autopsy control cases; in particular, there were no signs of
inflammation, hypoxia or neuronal damage. The interval
between death and autopsy ranged from 24 to 48 h (med-
ian = 24 h) in infarct, 10 to 24 h (median = 22 h) in TBI
and 8 to 120 h (median = 72 h) in control cases.
The study was carried out according to the national
ethics guidelines and legal regulations regarding the use
of archival post-mortem material. All patients and con-
trols, or their next of kin, had given informed consent for
autopsy.
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Histopathology
Specimens were fixed in 4 % paraformaldehyde and
embedded in paraffin. Sections 4 lm thick were stained
with hematoxylin and eosin (HE), luxol fast blue (LFB)/
periodic acid-Schiff (PAS) or Bielschowsky’s silver
impregnation. Immunohistochemical staining was per-
formed with a biotin–avidin or an alkaline phosphatase/
anti-alkaline phosphatase technique. The primary antibod-
ies used for diagnostic purposes were: anti-myelin basic
protein (anti-MBP, rabbit polyclonal, DakoCytomation,
Glostrup, Denmark), anti-proteolipid protein (anti-PLP,
mouse monoclonal, Biozol, Eching, Germany), anti-myelin
oligodendrocyte glycoprotein (anti-MOG, rat monoclonal,
kindly provided by Prof. Linington, University of Glasgow,
UK), anti-myelin-associated glycoprotein (anti-MAG,
rabbit polyclonal, kindly provided by Prof. Schwab,
University of Zu¨rich, Switzerland), anti-cyclic nucleotide
phosphodiesterase (anti-CNPase, mouse monoclonal,
Covance Inc., Princeton, NJ, USA), KiM1P (macro-
phages, mouse monoclonal, kindly provided by Prof.
Radzun, University of Go¨ttingen, Germany) and anti-
MRP14 (activated macrophages, mouse monoclonal, BMA
Biomedicals, Augst, Switzerland), anti-CD3 (T cells, rat
monoclonal, Serotec, UK), anti-CD8 (cytotoxic T cells,
rabbit polyclonal, Dako, Denmark), anti-glial fibrillary
acidic protein (anti-GFAP, rabbit polyclonal, Dako, Den-
mark), anti-IgG (plasma cells, rabbit polyclonal, Dako,
Denmark) and anti-complement C9neo antigen (anti-C9
neo, rabbit polyclonal, kindly provided by Prof. Morgan,
University of Cardiff, UK). In order to detect damaged
axons, we used anti-non-phosphorylated neurofilaments
(SMI32, mouse monoclonal, Sternberger MD, USA) and
anti-amyloid precursor protein (anti-APP, mouse mono-
clonal, Millipore, MA, USA). Wallerian degeneration was
visualized using anti-neuropeptide-Y1 receptor (anti-NPY-
Y1R, rabbit polyclonal, Acris Antibodies, Hiddenhausen,
Germany). PPWM in all the 44 tissue blocks demonstrated
normal myelin staining with the above-mentioned myelin
markers. The occurrence of microglial nodules was asses-
sed by anti-HLA-DR (MHC II, mouse monoclonal, clone
LN3, eBioscience, USA) (Fig. 1). All the detected mi-
croglial nodules and their surroundings were thoroughly
investigated to verify the absence of leukocyte infiltration
and astrogliosis on sequential tissue sections (data not
shown). Immunohistochemistry was performed on MS
biopsy tissue to detect expression of pro- and antiinflam-
matory markers in microglial nodules using antibodies
against CD40 (anti-CD40, rabbit polyclonal, Acris Anti-
bodies, Hiddenhausen, Germany), inducible nitric oxide
synthase (anti-iNOS, rabbit polyclonal, Millipore, MA,
USA), mannose receptor (anti-mannan binding protein,
mouse monoclonal, Serotec, UK) and CD163 (anti-CD163,
mouse monoclonal, Novo Laboratories, UK). Omission of
primary antibody served as a control staining.
The antibody against NPY-Y1R used in this study stains
degenerating nerve fibers and has been investigated in
epilepsy, brain infarct and MS tissue previously [19, 42].
However, the antigen detected by this antibody in degen-
erating axons remains unknown. In the present study, we
have further analyzed Wallerian degeneration in the axial
dimension of MS PPWM biopsy tissue sections using a
Z-stack module of confocal laser scanning microscopy. For
fluorescent staining, sections containing microglial nodules
were double-stained for HLA-DR and NPY-Y1R. Cy3-
labeled goat anti-mouse and Alexa 488-labeled goat anti-
rabbit were used as secondary antibodies.
Classification of multiple sclerosis lesions
All biopsy specimens fulfilled the generally accepted cri-
teria for the pathological diagnosis of MS, showing an
inflammatory demyelinating lesion [31, 44]. Lesions were
classified according to their demyelinating activity as
described in detail earlier [9]. Early active lesions were
infiltrated by numerous macrophages that are immunore-
active with major and minor myelin proteins (MBP, PLP,
MAG, MOG, CNP). In late active lesion areas, degradation
of myelin proteins was more advanced, and macrophages
contained only MBP- (and PLP-) but not MOG- (or MAG-)
positive myelin debris. Inactive lesions were completely
demyelinated, and macrophages no longer contained
myelin protein-positive degradation products within their
cytoplasm. In early remyelinating plaques, thin, irregularly
formed myelin sheaths were seen as well as a pronounced
infiltration by macrophages/microglial cells and T cells.
Remyelination was more advanced in late remyelinating
lesions, and only a few inflammatory cells could be found.
Image analysis and experimental details
Tissue sections were analyzed using an Olympus BX51
fluorescence microscope equipped with a DP71 CCD
camera (Olympus Optical Co, Ltd., Hamburg, Germany)
and a Zeiss Cell Observer microscope with an AxioCam ICc
3 CCD camera (Carl Zeiss MicroImaging, Ltd., Go¨ttingen,
Germany) or by confocal laser scanning microscopy with a
Fluoview 1000 Olympus microscope. All the images were
prepared in Adobe Photoshop CS4, version 11.0.2. The
numbers of cells constituting microglial nodules were
counted as visualized on HLA-DR stained sections using
light microscopy. For measuring the distances on tissue
section, the analySIS image processing software was used.
Evaluation of damaged axons associated with microglial
nodules was done by measuring the distance between the
nearest APP1/SMI321 axonal structure and nodule-
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forming nuclei. Three-dimensional reconstruction from
confocal Z-stack images was performed using Imaris Bit-
plane scientific software, version 7.5.
Statistical analysis
Differences in the number of microglial nodules against
lesion activity were statistically analyzed by Mann-Whit-
ney U test. Statistical analysis for the group difference
between microglial nodules containing APP-positive axo-
nal profiles and microglial nodules lacking APP-positive
axonal profiles was performed using non-parametric t tests.
Statistical significance was defined as p \ 0.05.
Results
Incidence of microglia nodules in white matter
from patients with early stage MS
To screen for microglial nodules, we examined PPWM
tissue from 27 biopsied MS patients with a median interval
from symptom onset to biopsy of 22.5 days (range, 3 days–
11 years). Identification of microglial nodules in the tissue
blocks containing PPWM was based on sequential immu-
nohistochemical staining of tissue sections for MHC II
(HLA-DR) and myelin markers, i.e., LFB/PAS, PLP, MBP,
MOG and MAG (Fig. 1). Microglial nodules (HLA-DR?)
showing variable morphologies, composed of four or more
cells, were observed in 16 patients (59.3 %) and 20 blocks
(45.5 %). The median number of cells constituting
microglial nodules was 9 cells per nodule and ranged from
4 to 18 cells per nodule. The median time to biopsy was
21 days (range, 3–44 days) for the patients containing
microglial nodule(s). We observed that the microglial
nodules in PPWM occurred more frequently in patients
with early active and late active lesions compared to
patients with inactive lesions (Table 1). However, the
quantitative determination of microglial nodules against
lesion activity revealed that microglial nodules in PPWM
occur irrespective of the plaque activity. There was no
significant difference in the number of nodules associated
with early active as compared to late and inactive lesions
(p = 0.11); similarly, no significant difference was found
Fig. 1 Microglial nodules are found in the normally myelinated
periplaque white matter in MS biopsy tissue. Staining for LFB/PAS
(a) and immunohistochemistry for PLP (b), MBP (c), MOG (d) and
MAG (e) on sequential tissue sections showed normal myelin (MS no.
7). Activated microglia/macrophages and circumscribed nodules
(arrows) that express HLA-DR are shown in (f). Insets in (b, c, d,
e, f) show higher magnification of the respective tissue immuno-
staining. Scale bars = (a–f) 250 lm
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in the number of nodules associated with active demyelin-
ating (i.e., both early and late active) lesions compared to
inactive lesions (p = 0.45). Nonetheless, we cannot exclude
the possibility that the studied PPWM region containing
microglial nodules could also be in the proximity of other
lesions not included in the studied tissue specimens. In
addition, the shortest possible distances between microglial
nodules and the nearest blood vessel present in the tissue
sections were measured; the median distance was calculated
at 541.76 lm (range 81.47–1,554.75). We further investi-
gated nodule-forming microglia/macrophages using the anti-
MRP14 antibody. Monocytes express MRP14 early in their
activation phase and during tissue invasion until their ter-
minal differentiation to macrophages, but none of the
microglial nodules or the surrounding microglia/macrophage
cells were found to be MRP14-positive on sequentially
stained tissue sections (data not shown) [9].
Microglial nodules are associated with damaged axons
in early MS
Sequential tissue sections of PPWM were immunostained
for HLA-DR and axonal damage markers, i.e., APP and
SMI32. Intra-axonal APP accumulation representing dis-
turbed axonal transport was observed along with terminal
ovoids resembling small bulbs, whereas SMI32 stained
morphologically intact axons as well as axons with alter-
nating constrictions or single swellings as dot-like ovoids.
Analysis of sequential tissue sections revealed that mi-
croglial nodules and surrounding activated microglia/
macrophages were associated with damaged axons (Fig. 2).
All 48 microglial nodules studied were found to be asso-
ciated with SMI321 axons, while APP1 axons and ovoids
were detected in more than half of the studied nodules
(Table 2). APP1/SMI321 axonal structures were detected
at a median distance of 4.22 lm (range 2.97–5.68) from the
nuclei of microglial nodules, which were considered to be
associated with damaged axons. A non-parametric t test
was performed to evaluate occurrence of microglial nod-
ules with APP? axonal structures; there was no significant
difference in the number of APP-positive and APP-nega-
tive nodules (p = 0.37).
Simultaneous detection of microglial nodules and axons
undergoing Wallerian degeneration
To investigate the relationship between microglial nodules
and the process of Wallerian degeneration, double-labeled
(i.e., HLA-DR and NPY-Y1R antibodies) immunostained
sections from nine cases (MS nos. 1, 3, 4, 5, 7, 9, 11, 13, 14)
were visualized using the confocal laser-scanning micros-
copy technique. All the 27 HLA-DR? nodules from
examined cases were found to be associated with NPY-Y1R?
structures (Table 2). The nodules were closely apposed to
and sometimes clustering around degenerating axons as well
as the activated, nodule-free microglia/macrophage cells
(Fig. 3). A direct spatial association was observed between
microglial nodules and axons undergoing Wallerian degen-
eration (Fig. 4). The presence of NPY-Y1R? fragments in
nodule-forming HLA-DR? microglia/macrophage cells
clearly underlines the functional relationship between
degenerating axons and microglial/macrophage reaction
(Fig. 5). This association is further visualized in Supplement
2. Quite intriguingly, not all NPY-Y1R? profiles were sur-
rounded by HLA-DR? cells, which might indicate axonal
degeneration is primary to microglia/macrophage activation
of the type seen in microglial nodules [47].
Table 1 Microglial nodule occurrence versus lesion activity





1 3 Inactive Left parietal
2 3 Inactive Right frontal
3 2 Late active Right occipital
4 7 Early active Corpus callosum
5 1 Late active Right frontal
6 9 Inactive Left occipital
7 3 Early active Right occipital
8 1 Early active Right frontal
9 4 Inactive Right frontal
10 1 Early active Left temporal
11 1 Late active Right parietal
12 4 Inactive Left parietal
13 5 Inactive Left temporal
14 1 Late active Left frontal
15 2 Early active Left occipital
16 1 Inactive Right frontal
17 Not present Inactive Right frontal
18 Not present Inactive Occipital
19 Not present Inactive Right frontal
20 Not present Inactive Right temporal
21 Not present Inactive Right frontal
22 Not present Inactive Right occipital
23 Not present Inactive Left temporal
24 Not present Late active Left frontal
25 Not present Inactive Left frontal
26 Not present Late active Right frontal
27 Not present Inactive Left frontal
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Microglial nodules are not specific to MS
To gain more insight into the prevalence of microglial
nodules, we systematically screened autopsy and biopsy
tissue from other neurological diseases (OND). Further
details of OND, i.e., infarct, TBI, epilepsy and control
cases, are summarized in Table 3. H&E, LFB/PAS and
HLA-DR staining was used to identify the nodules in
normal white matter tissue. The occurrence of microglial
nodules was observed in two TBI and all the seven infarct
patients, whereas nodules were absent in epilepsy and
non-neurological control patients. TBI and infarct lesions
were characterized by strong macrophage infiltration and
profound axonal loss and axonal spheroids; we found
abundant microglial nodules in the affected adjacent
normal white matter (Fig. 6a–d). In patients who under-
went surgery because of epilepsy, neuropathological
examination revealed no significant abnormalities except
for mild astrogliosis in two cases. Only a modest level of
microglia/macrophage activation was present in the
white matter; activated microglia/macrophages were
almost evenly dispersed, and no microglial/macrophage
clustering was observed in any of the epilepsy patients
(Fig. 6e) [7].
Expression of M1 and M2 markers in activated
microglia/macrophages and microglial nodules in MS
To determine the immune phenotype of microglial nodules
in MS, we analyzed the expression of pro- and antiinflam-
matory markers characteristic for M1 and M2 macrophages.
Microglia/macrophages associated with microglial nodules
express both pro- and antiinflammatory markers (Fig. 7).
Evaluation was performed on five cases (MS nos. 3, 6, 8, 13,
15) using antibodies against various surface proteins
involved in antigen presentation and recognition, i.e., CD40,
Fig. 2 Microglial nodules are associated with underlying axonal
pathology in early multiple sclerosis. LFB/PAS stain and HLA-DR
immunohistochemistry were used to identify microglial nodules in
PPWM (a, b). Sequential tissue sections (a, b, c, d) were matched
using a blood vessel (asterisk) (MS no. 5). The region of interest
exhibits intact myelin (a). Microglial nodule representing cluster of
activated HLA-DR expressing microglia/macrophages localized in
normally myelinated PPWM tissue (b). Sequential section identified
injured/damaged axons associated with microglial nodules (c, d).
APP?, acutely damaged axons are detected in close association with
the microglial nodule (c). SMI32?, axonal ovoids occur in the same
region (d and inset). Inset in (d) shows higher magnification of the
marked region. Scale bars = (a) 100 lm; (b–d) 50 lm
Table 2 Microglial nodules examined for damaged axons
Total number of nodules examined: 48
Nodules associated with APP? axons (%): 29 out of 48 (60.42 %)
Nodules associated with SMI32? axons (%): 48 out of 48 (100 %)
Nodules associated with NPY-Y1R? axons (%): 27 out of 27
(100 %)
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Fig. 3 Axons undergoing Wallerian degeneration in close spatial
association with activated microglia/macrophages in MS PPWM.
NPY-Y1R? axons (green) undergoing Wallerian degeneration
apposed to HLA-DR? microglia/macrophages (red) with an activated
morphology (arrows, a–b) (MS no. 14). NPY-Y1R? axons were fre-
quently surrounded by activated microglia/macrophages throughout
the PPWM (c–d) (MS no. 1). Activated microglia/macrophage cells
were visualized clustering along the length of the NPY-Y1R? axonal
segment (arrow, e–f) (MS no. 4). Stainings are merged with DAPI,
which stains the nuclei (a–f, blue). Scale bars = (a–b) 25 lm; (c–
d) 10 lm; (e–f) 20 lm
Fig. 4 Degenerating axons undergoing Wallerian degeneration associ-
ated with microglial nodule in MS. Fluorescent immunohistochemical
staining for HLA-DR (red) counterstained with DAPI (blue) shows a
microglial nodule consisting of several microglial/macrophage cells (MS
no. 11). The association of NPY-Y1R? fragments (green) with the
microglial nodule suggests Wallerian degeneration induced formation of
microglial nodule. Scale bar = 30 lm
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iNOS, mannose receptor and CD163. CD40 and iNOS,
proinflammatory molecules, were highly expressed
throughout the MS PPWM and frequently observed in
microglial nodules and activated microglia/macrophage
clusters. CD163, a marker for antiinflammatory M2 mac-
rophages, primarily stained perivascular macrophages but
Fig. 5 Intracellular NPY-Y1R?





(blue, a), NPY-Y1R? particles
(green, b) present within the
microglial/macrophage
cytoplasm (red, c). The merge is
shown in (d). The presence of
intracellular NPY-Y1R?
fragments (arrow) in nodule-
forming HLA-DR? cell
indicates engulfment of axonal
debris by activated microglia/
macrophages. Scale
bar = 15 lm
Table 3 Characteristics of OND and control cases
No. of cases Median age (years) F/M ratio Total no. of samples studieda No. of patients with
microglial nodule(s)
Infarct
Autopsy 4 59.5 (range, 43–86) 1/3 4 4
Biopsy 3 62 (range, 49–72) 0/3 5 3
TBI
Autopsy 3 44 (range, 18–47) 0/3 3 2
Epilepsy
Biopsy 7 39 (range, 28–48) 3/4 11 –
Normal controls Underlying disease Cause of death Age (years) Sex No. of samples studieda Microglial nodule(s)
1 None Multi-organ failure 51 M 2 –
2 None Aortic dissection 71 M 3 –
3 Unknown Acute cardiac failure 64 F 2 –
4 CAD Acute cardiac failure 58 F 1 –
5 Unknown Acute cardiac failure 37 F 1 –
CAD coronary artery disease
– no nodules detected in the any of the samples
a Only white matter region(s) present in each sample were studied
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was also present in parenchymal PPWM microglia/macro-
phages in two cases (MS nos. 8 and 13). In contrast, the
immunoreactivity of mannose receptor was mostly limited
to perivascular macrophages and was only occasionally
positive for parenchymal microglia/macrophages in PPWM
regions.
Fig. 6 Identification of microglial nodules in OND and MS.
Microglia/macrophage activation (HLA-DR?) throughout the perile-
sional white matter in the autopsy tissue from an infarct case (a).
b Represents a magnification of the region containing nodules in (a).
Microglial nodule in the white matter biopsy tissue from a patient
with cerebral infarction (c). White matter region surrounding
contusional lesion in an autopsy case (d). Disperse microglial/
macrophage activation in biopsied epilepsy white matter (e, inset).
Nodules present adjacent to the biopsied MS lesion in MS no. 3 (f).
Immunohistochemistry for HLA-DR: (a–f). Arrows: nodules. Scale
bars = (a, e) 250 lm; (b, d, f) 100 lm; (c) 25 lm
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Fig. 7 Microglial nodules in MS display both classically (M1) and
alternatively (M2) activated macrophage markers. CD40 was
expressed in cells associated with microglial nodules present in
PPWM (a) (MS no. 13). iNOS was present in phagocytes in
demyelinating MS lesions and very frequently found to be expressed
in the clusters forming a small foci of microglial/macrophage cells
(arrows) in PPWM (b, c) (MS no. 6). c Represents a higher
magnification of the PPWM region marked with black box in (b). M2
marker mannose receptor was present perivascularly (inset of d) and
was only rarely expressed on parenchymal cells (arrowheads) in
PPWM (d) (MS no. 13). CD163 was detected in activated microglia/
macrophages and microglial nodules (arrow) as well as in perivas-
cular spaces (arrowhead) (d) (MS no. 8). Scale bars = (a, d, e)
100 lm; (b) 200 lm; (c) 50 lm
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Discussion
Our present study shows that microglial nodules are asso-
ciated with damaged axons in early MS PPWM. Intra-
axonal APP accumulation and changes of neurofilament
phosphorylation served as a markers for axonal damage.
Axons undergoing Wallerian degeneration showed granu-
lar degeneration and were detected using the anti-NPY-
Y1R antibody. Here, we sought to clarify that microglial
nodule formation is reactive in early MS white matter.
Over the last 2 decades, microglial nodules have been
frequently noted in MS pathology. Prineas and colleagues
[1, 45] detected deposits of activated complement (C3d) in
elongated microglial nodules in MS PPWM, which sug-
gests complement-mediated clustering of activated
microglia/macrophages. Another study illustrated the role
of oligodendrocyte stress in microglial nodules, although
the ultimate cause of this abnormality remains unclear [55].
However, oligodendrocytes exist in close relationship with
axons; thus, stressed axons might very well serve as an
initiating source. These data together with our findings may
explain that Wallerian degeneration precedes oligoden-
drocyte stress and complement activation in the course of
microglial nodule formation.
Microglial nodules were observed irrespective of disease
duration in MS NAWM [46, 54]. One particular report
studied 52 post-mortem MS cases and illustrated that the
incidence of microglial nodules decreases with the increase
in disease duration [46]. Given that most of the microglial/
macrophage clusters in MS were found to be present in close
vicinity to demyelinated plaques [46, 52, 54], we considered
a cohort of biopsied patients with median disease duration of
22.5 days ideal for studying microglial nodules close to
disease onset. Our data, in contrast to prior studies based on
autopsy material from chronic MS patients, found altered/
damaged axons associated with microglial nodules. Previous
neuropathological findings addressing structural damage in
MS lesions support the idea that the occurrence of microglial
nodules in MS is reactive [6, 21, 29]. Stainings in the PPWM-
containing nodules appeared normal for all the given myelin
markers, a finding that further rules out myelin abnormalities
as the primary trigger [46, 54]. This in turn also supports that
myelin breakdown/clearance is a delayed and slow process
in CNS Wallerian degeneration [47, 56]. Neuroradiological
observations showing an association of regional lesion load
and axonal density in related NAWM suggest that the
observed abnormalities in non-demyelinated white matter
may have at least partly developed as a result of axonal
transections within lesions [14, 20, 37, 59]. In line with this,
the presence of NPY-Y1R? axons within the microglial
nodules indicates that these nodules may have formed as
outcome sequelae of Wallerian degeneration in PPWM
caused by lesional pathology.
Indeed, microglial nodules are regularly seen in brain
trauma [22], and in this study, supporting the earlier find-
ing, we observed microglial nodules in the perilesional
white matter of brain infarcts and TBI lesions but not in
epilepsy and control cases. Also, in our previous study, we
demonstrated high numbers of NPY-Y1R? degenerating
axons in infarct tissue while axonal degeneration was vir-
tually absent in epilepsy patients. This underlines that the
microglial nodules in CNS white matter tend to occur in
overt axonal degenerative conditions and therefore may
develop in various brain disorders. Microglial nodule for-
mation induced by anterograde axonal degeneration was
also observed in mice, which further supports the notion
that the event of nodule formation is driven by axonal
degeneration in CNS white matter [16]. Recent magnetic
resonance 7T T2* imaging studies revealed that MS white
matter lesions are perivenous [17, 50]. Besides MS, acute
disseminated encephalomyelitis (ADEM) and even exper-
imental autoimmune encephalomyelitis (EAE) lesions are
known to develop as a rule around a central vein(s) [28, 32,
60]. On this basis, it seems uncertain that the microglial
nodules in MS can expand to form a new, full-blown
demyelinating lesion involving a pathogenesis that excludes
blood-brain barrier alterations. However, De Groot et al.
[13] also described clusters of microglial/macrophage cells
contiguous with blood vessels containing CD45-positive
lymphocytes as (p)reactive; in this context, we did not find
any microglial nodule directly linked with blood vessels in
the present study [54].
Our results also suggest that mechanisms other than
Wallerian degeneration may contribute to axonal damage
associated with microglial nodules in MS. The association
of SMI32? axons and frequent accumulation of APP?
axonal end bulbs with microglial nodules and the sur-
rounding activated microglia/macrophages in MS white
matter supports the hypothesis that microglial inflamma-
tion can have detrimental effects and mediate axonal
damage [24, 30, 38, 41]. Previous reports demonstrated that
inflammatory mediators secreted from activated microglia/
macrophages such as matrix metalloproteinases, proin-
flammatory cytokines, nitric oxide and reactive oxygen
species may cause disruption of axoplasmic transport and
axon integrity, eventually leading to axotomy [4, 15, 39,
40, 49]. Maeda and Sobel [34] detected matrix metallo-
proteinases activity, while van Horssen et al. [54] observed
NADPH oxidase, TNF-alpha and IL-10 expression in MS
microglial nodules. Interestingly, we observed strong
CD40, iNOS and CD163 expression in these foci. This may
explain the inconsistency in the occurrence of APP? axonal
profiles in microglial nodules, i.e., that antiinflammatory
mechanisms could possibly restrain the damage caused in
response to focal microglia/macrophage activation. Despite
this, we do not have a complete explanation for these
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phenotypes. However, the time factor following the trigger
could play a decisive role, as the initial proinflammatory
niche of activated microglia/macrophages appears to shift
towards the antiinflammatory [8]. Yet, all the nodules
studied contained SMI32? profiles, which further suggests
that the axons in PPWM/NAWM are more susceptible to
altered patterns of phosphorylation of neurofilament pro-
teins as compared to intra-axonal APP accumulation [19].
Another possible cause for APP? and SMI32? axonal
structures detected in PPWM could be a direct anti-axonal
immune response, e.g., anti-neurofascin antibodies, which
selectively target neurofascin at the nodes of Ranvier in
animal models and may subsequently lead to local
microglia/macrophage activation [35].
In conclusion, the functional relationship between NPY-
Y1R? axons and microglial nodules observed in this study
demonstrate that the process of axonal degeneration may
cause microglial nodule formation, at least in early MS
PPWM. In light of this, our data do not appear to concur
with the notion that the pathogenesis of (p)reactive lesions
is similar to other analogous MS lesions, such as pattern III
lesions and newly forming lesions, both of which are
clearly described in terms of oligodendrogliopathy and
myelin loss [2, 33]. Considering the fact that pathology can
provide only a snapshot of an on-going course of action in
the evolving disease, immune-regulatory phenotyping of
such nodules in MS may reveal its overall significance in
the disease.
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